FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the ...

Melanoma, the deadliest form of skin cancer, is often driven by mutations in the BRAF gene, which fuels uncontrolled tumor ...

It will take about four months to build out the 17,708-square-foot space; the foundation expects to move in during August.

To fight this, doctors often use drugs called BRAF inhibitors, such as vemurafenib, which can stop the cancer’s growth—at ...

Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced two plixorafenib abstracts have been ...

As we have reported, the BRAF and RAS mutant tumors are more sensitive to ERK pathway inhibition than the RAF/RAS wild type tumors. We are now investigating the biochemical actions and anti-tumor ...